Successful Reprogramming of Cellular Protein Production Through MRNA Delivered by Functionalized Lipid Nanoparticles

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2018 Mar 29

PMID 29588418

Citations 173

Authors

Marianna Yanez Arteta

Tomas Kjellman

Stefano Bartesaghi

Simonetta Wallin

Xiaoqiu Wu

Alexander J Kvist

Aleksandra Dabkowska

Noemi Szekely

Aurel Radulescu

Johan Bergenholtz

Lennart Lindfors

Affiliations

Soon will be listed here.

Abstract

The development of safe and efficacious gene vectors has limited greatly the potential for therapeutic treatments based on messenger RNA (mRNA). Lipid nanoparticles (LNPs) formed by an ionizable cationic lipid (here DLin-MC3-DMA), helper lipids (distearoylphosphatidylcholine, DSPC, and cholesterol), and a poly(ethylene glycol) (PEG) lipid have been identified as very promising delivery vectors of short interfering RNA (siRNA) in different clinical phases; however, delivery of high-molecular weight RNA has been proven much more demanding. Herein we elucidate the structure of hEPO modified mRNA-containing LNPs of different sizes and show how structural differences affect transfection of human adipocytes and hepatocytes, two clinically relevant cell types. Employing small-angle scattering, we demonstrate that LNPs have a disordered inverse hexagonal internal structure with a characteristic distance around 6 nm in presence of mRNA, whereas LNPs containing no mRNA do not display this structure. Furthermore, using contrast variation small-angle neutron scattering, we show that one of the lipid components, DSPC, is localized mainly at the surface of mRNA-containing LNPs. By varying LNP size and surface composition we demonstrate that both size and structure have significant influence on intracellular protein production. As an example, in both human adipocytes and hepatocytes, protein expression levels for 130 nm LNPs can differ as much as 50-fold depending on their surface characteristics, likely due to a difference in the ability of LNP fusion with the early endosome membrane. We consider these discoveries to be fundamental and opening up new possibilities for rational design of synthetic nanoscopic vehicles for mRNA delivery.

Citing Articles

mRNA lipid nanoparticle formulation, characterization and evaluation.

Ma Y, VanKeulen-Miller R, Fenton O Nat Protoc. 2025; .

PMID: 40069324 DOI: 10.1038/s41596-024-01134-4.

The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.

Zhang J, Zeng F, Li Y, Mu C, Liu C, Wang L Hum Vaccin Immunother. 2025; 21(1):2473183.

PMID: 40045463 PMC: 11901403. DOI: 10.1080/21645515.2025.2473183.

Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review.

Idres Y, Idris A, Gao W Drug Deliv Transl Res. 2025; .

PMID: 40000558 DOI: 10.1007/s13346-025-01815-x.

Reply to Trollmann et al.: Perspective on LNP structure and simulation.

Garaizar A, Diaz-Oviedo D, Zablowsky N, Rissanen S, Kobberling J, Sun J Proc Natl Acad Sci U S A. 2025; 122(9):e2423433122.

PMID: 39993199 PMC: 11892676. DOI: 10.1073/pnas.2423433122.

Revisiting lipid nanoparticle composition and structure: A critical take on simulation approaches.

Trollmann M, Rossetti P, Bockmann R Proc Natl Acad Sci U S A. 2025; 122(9):e2422995122.

PMID: 39993184 PMC: 11892627. DOI: 10.1073/pnas.2422995122.

References

Leung A, Tam Y, Chen S, Hafez I, Cullis P . Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. J Phys Chem B. 2015; 119(28):8698-706. DOI: 10.1021/acs.jpcb.5b02891. View

Barros S, Gollob J . Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev. 2012; 64(15):1730-7. DOI: 10.1016/j.addr.2012.06.007. View

Kormann M, Hasenpusch G, Aneja M, Nica G, Flemmer A, Herber-Jonat S . Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011; 29(2):154-7. DOI: 10.1038/nbt.1733. View

Belliveau N, Huft J, Lin P, Chen S, Leung A, Leaver T . Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids. 2013; 1:e37. PMC: 3442367. DOI: 10.1038/mtna.2012.28. View

Marsh D, Bartucci R, Sportelli L . Lipid membranes with grafted polymers: physicochemical aspects. Biochim Biophys Acta. 2003; 1615(1-2):33-59. DOI: 10.1016/s0005-2736(03)00197-4. View

Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S . Size-Dependent Endocytosis of Nanoparticles. Adv Mater. 2009; 21:419-424. PMC: 2709876. DOI: 10.1002/adma.200801393. View

Zangi L, Lui K, von Gise A, Ma Q, Ebina W, Ptaszek L . Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 2013; 31(10):898-907. PMC: 4058317. DOI: 10.1038/nbt.2682. View

Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D . Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-55. DOI: 10.1038/nrg3763. View

Chen S, Tam Y, Lin P, Sung M, Tam Y, Cullis P . Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release. 2016; 235:236-244. DOI: 10.1016/j.jconrel.2016.05.059. View

10.

Dan N, Danino D . Structure and kinetics of lipid-nucleic acid complexes. Adv Colloid Interface Sci. 2014; 205:230-9. DOI: 10.1016/j.cis.2014.01.013. View

11.

Zackrisson M, Stradner A, Schurtenberger P, Bergenholtz J . Small-angle neutron scattering on a core-shell colloidal system: a contrast-variation study. Langmuir. 2005; 21(23):10835-45. DOI: 10.1021/la051664v. View

12.

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U . Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013; 31(7):638-46. DOI: 10.1038/nbt.2612. View

13.

Patel S, Ashwanikumar N, Robinson E, DuRoss A, Sun C, Murphy-Benenato K . Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. Nano Lett. 2017; 17(9):5711-5718. PMC: 5623340. DOI: 10.1021/acs.nanolett.7b02664. View

14.

Dowdy S . Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017; 35(3):222-229. DOI: 10.1038/nbt.3802. View

15.

Junquera E, Aicart E . Recent progress in gene therapy to deliver nucleic acids with multivalent cationic vectors. Adv Colloid Interface Sci. 2015; 233:161-175. DOI: 10.1016/j.cis.2015.07.003. View

16.

Kenworthy A, Hristova K, Needham D, McIntosh T . Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J. 1995; 68(5):1921-36. PMC: 1282095. DOI: 10.1016/S0006-3495(95)80369-3. View

17.

Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui B, Tam Y . Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015; 217:345-51. PMC: 4624045. DOI: 10.1016/j.jconrel.2015.08.007. View

18.

Wang Y, Su H, Yang Y, Hu Y, Zhang L, Blancafort P . Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2012; 21(2):358-67. PMC: 3594035. DOI: 10.1038/mt.2012.250. View

19.

Leung A, Hafez I, Baoukina S, Belliveau N, Zhigaltsev I, Afshinmanesh E . Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces. 2012; 116(34):18440-18450. PMC: 3434764. DOI: 10.1021/jp303267y. View

20.

Bartesaghi S, Hallen S, Huang L, Svensson P, Momo R, Wallin S . Thermogenic activity of UCP1 in human white fat-derived beige adipocytes. Mol Endocrinol. 2014; 29(1):130-9. PMC: 5414770. DOI: 10.1210/me.2014-1295. View